2015
HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era
Grew D, Bitterman D, Leichman CG, Leichman L, Sanfilippo N, Moore HG, Du K. HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era. Diseases Of The Colon & Rectum 2015, 58: 1130-1136. PMID: 26544809, DOI: 10.1097/dcr.0000000000000476.Peer-Reviewed Original ResearchConceptsHIV-negative patientsHIV-positive patientsActive antiretroviral therapy (HAART) eraAntiretroviral therapy eraColostomy-free survivalOverall survival rateAnal cancerSurvival rateTherapy eraMultivariate analysisColostomy-free survival ratesLocal recurrence-free survivalDistant metastasis-free survivalRetrospective chart reviewSmall patient numbersRecurrence-free survivalMetastasis-free survivalOutpatient oncology clinicsLarge academic centerDefinitive chemoradiationDefinitive chemoradiotherapyChart reviewOverall survivalPatient characteristicsHIV infection
2014
Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials
Min C, Bangalore S, Jhawar S, Guo Y, Nicholson J, Formenti SC, Leichman LP, Du KL. Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials. Oncology 2014, 86: 79-85. PMID: 24435019, DOI: 10.1159/000354641.Peer-Reviewed Original ResearchConceptsDisease-free survivalAdjuvant chemoradiationSurgical resectionOverall survivalRandomized trialsGastric cancerMantel-Haenszel random-effects modelHigher disease-free survivalCategory 1 recommendationNew systemic agentsR0 surgical resectionCurrent national guidelinesSignificant differencesRandom-effects modelAdjuvant chemotherapyPerioperative chemotherapyChemotherapy regimenChemoradiation therapySystemic agentsPrimary outcomeGastric adenocarcinomaClinical trialsChemoradiationNational guidelinesResection
2006
Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer
Du KL, Mick R, Busch TM, Zhu TC, Finlay JC, Yu G, Yodh AG, Malkowicz SB, Smith D, Whittington R, Stripp D, Hahn SM. Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer. Lasers In Surgery And Medicine 2006, 38: 427-434. PMID: 16788929, DOI: 10.1002/lsm.20341.Peer-Reviewed Original ResearchConceptsInterstitial photodynamic therapyProstate adenocarcinomaProstate cancerPhotodynamic therapyRecurrent prostate adenocarcinomaSolid organ diseaseSubsequent tissue necrosisOrgan diseaseDrug levelsPreclinical studiesClinical experienceSTUDY DESIGN/MATERIALSTissue necrosisDose distributionDESIGN/MATERIALSPhase IAdenocarcinomaHuman subjectsProstateCancerTreatmentUniversity of PennsylvaniaDose variationComprehensive treatmentPatients